240 related articles for article (PubMed ID: 21062081)
1. Histamine H3 receptor as a drug discovery target.
Berlin M; Boyce CW; Ruiz Mde L
J Med Chem; 2011 Jan; 54(1):26-53. PubMed ID: 21062081
[No Abstract] [Full Text] [Related]
2. The histamine H3 receptor as a therapeutic drug target for CNS disorders.
Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D
Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511
[TBL] [Abstract][Full Text] [Related]
3. Several down, a few to go: histamine H3 receptor ligands making the final push towards the market?
Kuhne S; Wijtmans M; Lim HD; Leurs R; de Esch IJ
Expert Opin Investig Drugs; 2011 Dec; 20(12):1629-48. PubMed ID: 21992603
[TBL] [Abstract][Full Text] [Related]
4. H3 receptor antagonists/inverse agonists as anti-obesity agents.
Hancock AA
Curr Opin Investig Drugs; 2003 Oct; 4(10):1190-7. PubMed ID: 14649210
[TBL] [Abstract][Full Text] [Related]
5. [The histamine H(3) receptor: a target for new drugs].
Arrang JM
Ann Pharm Fr; 2003 May; 61(3):173-84. PubMed ID: 12714930
[TBL] [Abstract][Full Text] [Related]
6. Recent medicinal chemistry of the histamine H3 receptor.
Letavic MA; Barbier AJ; Dvorak CA; Carruthers NI
Prog Med Chem; 2006; 44():181-206. PubMed ID: 16697898
[No Abstract] [Full Text] [Related]
7. Histamine-selective H3 receptor ligands and cognitive functions: an overview.
Vohora D
IDrugs; 2004 Jul; 7(7):667-73. PubMed ID: 15243869
[TBL] [Abstract][Full Text] [Related]
8. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
Hancock AA
Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
[TBL] [Abstract][Full Text] [Related]
9. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
[TBL] [Abstract][Full Text] [Related]
10. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders.
Passani MB; Lin JS; Hancock A; Crochet S; Blandina P
Trends Pharmacol Sci; 2004 Dec; 25(12):618-25. PubMed ID: 15530639
[TBL] [Abstract][Full Text] [Related]
11. [Possible roles of brain histamine H3 receptors and the pharmacology of its ligands].
Onodera K; Watanabe T
Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Apr; 15(2):87-102. PubMed ID: 7796325
[TBL] [Abstract][Full Text] [Related]
12. Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists.
Hancock AA; Brune ME
Expert Opin Investig Drugs; 2005 Mar; 14(3):223-41. PubMed ID: 15833055
[TBL] [Abstract][Full Text] [Related]
13. Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.
Schneider EH; Strasser A; Thurmond RL; Seifert R
J Pharmacol Exp Ther; 2010 Aug; 334(2):513-21. PubMed ID: 20484153
[TBL] [Abstract][Full Text] [Related]
14. Unexpected partial H1-receptor agonism of imidazole-type histamine H3-receptor antagonists lacking a basic side chain.
Sadek B; Elz S; Pertz HH; Stark H; Schunack W
Inflamm Res; 2004 Aug; 53 Suppl 2():S109-15. PubMed ID: 15338060
[TBL] [Abstract][Full Text] [Related]
15. Differences in pharmacological properties of histamine H(3) receptor agonists and antagonists revealed at two human H (3) receptor isoforms.
Esbenshade TA; Krueger KM; Yao BB; Witte DG; Estvander BR; Baranowski JL; Miller TR; Hancock AA
Inflamm Res; 2006 Apr; 55 Suppl 1():S45-6. PubMed ID: 16705378
[No Abstract] [Full Text] [Related]
16. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
Esbenshade TA; Fox GB; Cowart MD
Mol Interv; 2006 Apr; 6(2):77-88, 59. PubMed ID: 16565470
[TBL] [Abstract][Full Text] [Related]
17. Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.
Hancock AA; Diehl MS; Fey TA; Bush EN; Faghih R; Miller TR; Krueger KM; Pratt JK; Cowart MD; Dickinson RW; Shapiro R; Knourek-Segel VE; Droz BA; McDowell CA; Krishna G; Brune ME; Esbenshade TA; Jacobson PB
Inflamm Res; 2005 Apr; 54 Suppl 1():S27-9. PubMed ID: 15928821
[No Abstract] [Full Text] [Related]
18. Neuronal histamine and its receptors: implication of the pharmacological treatment of obesity.
Masaki T; Yoshimatsu H
Curr Med Chem; 2010; 17(36):4587-92. PubMed ID: 21062248
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
20. Covalent Inhibition of the Histamine H
Wágner G; Mocking TAM; Kooistra AJ; Slynko I; Ábrányi-Balogh P; Keserű GM; Wijtmans M; Vischer HF; de Esch IJP; Leurs R
Molecules; 2019 Dec; 24(24):. PubMed ID: 31835873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
